PCOS in Perimenopause: What Changes, What Persists, What Is Missed

What actually changes in PCOS during perimenopause?

Menstrual cycles frequently regularize as PCOS moves through perimenopause, and this is a mechanical consequence of ovarian aging rather than a sign the underlying condition has resolved — a pattern seen across the different phenotypes, not just one. A small but detailed 2003 study of 27 women with PCOS aged 35.8 to 49.4 compared those who had developed regular cycles (n=20) with those who remained irregular (n=7), and found the regularly cycling group had a smaller ultrasound follicle count — a median of 8.5 compared with 18.0 — were significantly older, and had lower androgens. The study’s conclusion was direct: the shrinking follicle cohort that comes with ovarian aging is what is producing the more regular cycle, not a reversal of the syndrome. The excess follicle pool that drove anovulation for decades is depleting the same way it does in ovarian aging generally — it is simply depleting from a higher starting number in PCOS.

Why do PCOS cycles become more regular with age?

Ovulation becomes more frequent as the antral follicle count that PCOS ovaries carry in excess falls toward the range seen in ovaries without PCOS, removing the multi-follicular arrest pattern that kept ovulation from completing. This means the “regular cycles” phase many people experience in their late 30s and 40s is a marker of a shrinking ovarian reserve, not a recovery — a distinction that matters for anyone using cycle regularity as a signal that fertility is improving, when the more likely explanation is the opposite.

What persists after menopause: androgens, SHBG, and metabolic risk

Hyperandrogenism and metabolic risk markers stay significantly elevated in PCOS compared with age-matched peers well past menopause, according to the most complete evidence synthesis on this question. A 2023 systematic review and meta-analysis pooling 28 studies of women 45 and older found peri- and postmenopausal women with PCOS had significantly higher total testosterone (standardized mean difference, SMD, 0.78), a markedly higher free androgen index (SMD 1.29), and lower SHBG (SMD -0.60) than controls of the same age. The same review found higher HOMA-IR (SMD 0.56), fasting insulin (SMD 0.61) and fasting glucose (SMD 0.48), alongside roughly three times the odds of diabetes (OR 3.01) and 79% higher odds of hypertension (OR 1.79) compared with age-matched controls. Even in the subset of studies that matched PCOS and control groups on BMI, one difference held up on its own: lower HDL cholesterol persisted regardless of body weight, and postmenopausal androgen levels stayed elevated in the studies where weight was matched — evidence the hyperandrogenism itself, not just coexisting weight, is doing some of this.

A separate, decades-long cohort followed a smaller group of women with PCOS from perimenopause into extreme old age and found a similar picture from a different angle. In women with PCOS re-examined at a mean age of 81, first assessed in 1987 and followed for over 30 years, testosterone and the free androgen index had continued to decline with age, while SHBG had continued to rise — the opposite trajectory some assume, since SHBG is usually thought of as suppressed in PCOS. Despite that decline, the group remained significantly more hirsute than age-matched controls even at that age (33% versus 4%), and FSH stayed lower than controls (50 versus 70 IU/L) decades after menopause — a marker that clinical hyperandrogenism can outlast the biochemical numbers that are supposed to explain it.

Does PCOS go away with menopause?

No single study answers this cleanly, and the honest answer is that some features fade while others do not. Hyperandrogenism — the defining feature of most PCOS phenotypes — measurably declines with age within the same women, based on the perimenopause-to-80-plus follow-up above, yet stays elevated relative to age-matched peers who never had PCOS. Metabolic risk, tracked across the larger meta-analysis, does not fade at all by the numbers available: the odds ratios for diabetes and hypertension come from studies of women who are, by definition, already past the reproductive years where PCOS is usually diagnosed and managed. What is genuinely uncertain is whether that persistent risk translates into more heart attacks, strokes or earlier death very late in life — the longest-followed cohort available found no significant excess mortality by a mean age of 81, though its authors are explicit that the study was underpowered to rule a true difference out. The fair summary: the ovulation problem that got most people diagnosed becomes irrelevant after menopause, since nobody ovulates then; the metabolic and androgen profile that came with it mostly does not disappear on the same timeline.

What PCOS symptoms show up differently in your 40s?

Cycle irregularity, the symptom that drove most PCOS diagnoses in the first place, becomes a less useful signal through the 40s as it converges with the irregularity of the perimenopausal transition itself — everyone’s cycles become less predictable approaching menopause, PCOS or not, which is part of what makes this decade diagnostically confusing rather than clarifying. Hirsutism and androgenic symptoms tend to persist more than cycle symptoms do, consistent with the pattern in the cohort followed to age 81 above. Weight gain specifically does not appear to accelerate beyond what happens to everyone else in this decade: the 24-year Swedish follow-up cited above found the yearly increase in BMI and waist-to-hip ratio was similar between women with PCOS and controls through the transition to menopause. What changes is not the rate of weight gain but its consequence — the same insulin resistance that was present all along compounds with ordinary age-related metabolic change, harder glucose control, and climbing blood pressure, rather than appearing new. What actually changes about exercise programming for PCOS at this stage covers how to adjust for that shift rather than following the same plan that worked at 25. New night sweats or 3am waking in this decade get assumed to be perimenopause by default, but PCOS is linked to a later transition than average, not an earlier one — so the other, more common causes of night sweats worth ruling out first usually deserve a look before the timeline is blamed on menopause starting.

Why is a PCOS diagnosis harder to confirm in perimenopause?

Two of the three Rotterdam criteria become less reliable as a woman approaches menopause, which is why a first diagnosis in the 40s is often harder to pin down than the same diagnosis at 25. The ovulation criterion loses discriminating power because cycle irregularity from ordinary ovarian aging looks similar to PCOS-driven anovulation on the surface, and the two are genuinely difficult to tell apart without a longer history. The ultrasound and AMH criteria run into the same problem from the other direction: antral follicle count and AMH decline with age in every ovary, with or without PCOS, so a scan or blood draw that would have clearly shown polycystic morphology at 25 can look ordinary at 45 even in a person who has had PCOS the whole time. The 2023 international guideline builds its diagnostic framework primarily around the reproductive years for exactly this reason, leaving perimenopausal and postmenopausal diagnosis to rest more heavily on history — a documented pattern of androgen excess or irregular cycles earlier in life — than on a fresh scan or hormone panel taken for the first time in perimenopause. Anyone piecing that history together for the first time in their 40s benefits from working through the full PCOS diagnostic criteria with a clinician rather than relying on a single test.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. The diagnostic and monitoring picture in this article is unchanged by the rename; this article uses PCOS because that is still the term most readers search.

What screening still applies after menopause?

Metabolic screening does not stop being relevant once the reproductive criteria for PCOS stop applying, and the numbers above are the reason why: a threefold higher odds of diabetes and a 79% higher odds of hypertension, measured in women already past 45, are not risks that resolve on their own with age. An oral glucose tolerance test with insulin, a fasting lipid panel, and blood pressure checks all remain relevant on the same schedule they would for a younger person with PCOS — arguably more so, since the 24-year follow-up data above shows diabetes risk compounding with time rather than leveling off. Androgen testing is less useful as a stand-alone screening tool at this stage, since total and free testosterone decline with age even while remaining relatively elevated against peers, which makes a single postmenopausal reading harder to interpret without a baseline from earlier in life.

Why bleeding changes in this decade need a specific answer

Years of anovulatory cycles mean years of oestrogen stimulating the uterine lining without progesterone prompting it to shed on schedule, and the 2023 international guideline is explicit that premenopausal women with PCOS carry a markedly raised risk of endometrial hyperplasia and endometrial cancer as a result. It compounds with long-standing absent periods, higher body weight and type 2 diabetes.

The overall chance stays low and the guideline does not recommend routine screening for everyone with PCOS. What matters in this decade specifically is the attribution problem: irregular or heavier bleeding at 45 is easy to file under perimenopause, and a PCOS history makes it easier still. Heavy or prolonged bleeding and endometrial hyperplasia in PCOS each cover what assessment involves.

Who this doesn’t work for

None of the longitudinal data above comes from large, randomly sampled populations — the two Swedish cohorts cited here followed fewer than 40 women with PCOS each across decades, and the 2023 meta-analysis itself notes substantial heterogeneity in how PCOS was originally diagnosed across its 28 included studies. This is not a reason to dismiss the findings, but it does mean the specific effect sizes should be read as a consistent direction rather than a precise, individually applicable number. This article also does not apply to reading a first-ever hormone panel or ultrasound taken in your 40s as if it carries the same diagnostic weight it would in your 20s — the guideline framework this site otherwise relies on was built and validated primarily for reproductive-age diagnosis, not for a new diagnosis attempted for the first time during the menopausal transition.